

CLINICAL CANCER RESEARCH

TABLE OF CONTENTS

HIGHLIGHTS

4665 Selected Articles from This Issue

SPECIAL FEATURES

CCR Translations

4667 **ATR Inhibitors and Paclitaxel in Melanoma**
Alan Ashworth
See related article, p. 4700

Review

4669 **Tumor Immune Microenvironment during Epithelial-Mesenchymal Transition**
A C Mana Taki, Kaoru Abiko, Masayo Ukita, Ryusuke Murakami, Koji Yamanoi, Ken Yamaguchi, Junzo Hamanishi, Tsukasa Baba, Noriomi Matsumura, and Masaki Mandai

CCR Drug Updates

4680 **FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma**
Sandra J. Casak, Leigh Marcus, Lola Fashoyin-Aje, Sirisha L. Mushti, Joyce Cheng, Yuan-Li Shen, William F. Pierce, Leah Her, Kirsten B. Goldberg, Marc R. Theoret, Paul G. Kluetz, Richard Pazdur, and Steven J. Lemery

4685 **FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors**
Leigh Marcus, Lola A. Fashoyin-Aje, Martha Donoghue, Mengdie Yuan, Lisa Rodriguez, Pamela S. Gallagher, Reena Philip, Soma Ghosh, Marc R. Theoret, Julia A. Beaver, Richard Pazdur, and Steven J. Lemery

RESEARCH BRIEFS: CLINICAL TRIAL BRIEF REPORTS

4690 **Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study**
Matthew S. Davids, Andrew W. Roberts, Vaishalee P. Kenkre, William G. Wierda, Abhijeet Kumar, Thomas J. Kipps, Michelle Boyer, Ahmed Hamed Salem, John C. Pesko, Jennifer A. Arzt, Margaret Mantas, Su Y. Kim, and John F. Seymour

4696 **Patient-Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY)**
Judy C. Boughey, Vera J. Suman, Jia Yu, Katelyn Santo, Jason P. Sinnwell, Jodi M. Carter, Krishna R. Kalari, Xiaojia Tang, Sarah A. McLaughlin, Alvaro Moreno-Aspitia, Donald W. Northfelt, Richard J. Gray, Katie N. Hunt, Amy Lynn Conners, James N. Ingle, Ann Moyer, Richard Weinshilboum, John A. Copland III, Liewei Wang, and Matthew P. Goetz

CLINICAL TRIALS: TARGETED THERAPY

4700 **Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer**
Seung Tae Kim, Simon A. Smith, Peter Mortimer, Arsene-Bienvenu Loembé, Heejin Cho, Kyoung-Mee Kim, Claire Smith, Sophie Willis, Itziar Irurzun-Arana, Alienor Berges, Jung Yong Hong, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Iwanka Kozarewa, Andrew J. Pierce, Emma Dean, and Jeeyun Lee
See related commentary, p. 4667

4710 **Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors**
Khanh T. Do, Bose Kochupurakkal, Sarah Kelland, Adrienne de Jonge, Jennifer Hedglin, Allison Powers, Nicholas Quinn, Courtney Gannon, Loan Vuong, Kalindi Parmar, Jean-Bernard Lazaro, Alan D. D'Andrea, and Geoffrey I. Shapiro

TABLE OF CONTENTS

4717 Phase II Open-Label, Single-Arm Trial to Investigate the Efficacy and Safety of Topical Remetinostat Gel in Patients with Basal Cell Carcinoma

James M. Kilgour, Aatman Shah, Nicole M. Urman, Shaundra Eichstadt, Hanh N. Do, Irene Bailey, Amar Mirza, Shufeng Li, Anthony E. Oro, Sumaira Z. Aasi, and Kavita Y. Sarin

CLINICAL TRIALS: IMMUNOTHERAPY

4726 Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma

Joseph M. Tuscano, Christina Poh, Paul Kaesberg, Guillaume Luxardi, Alexander Merleev, Alina Marusina, Ann Brunson, Aaron Rosenberg, Brian Jonas, and Emanuel Maverakis

4737 Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases

Anna Maria Di Giacomo, Vanna Chiarion-Sileni, Michele Del Vecchio, Pier Francesco Ferrucci, Michele Guida, Pietro Quaglino, Massimo Guidoboni, Paolo Marchetti, Ornella Cutaia, Giovanni Amato, Alessia Covre, Roberto Camerini, Luana Calabrò, Monica Valente, Diana Giannarelli, Mario Mandalà, and Michele Maio

4746 A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer

Lawrence Fong, Michael J. Morris, Oliver Sartor, Celestia S. Higano, Lance Pagliaro, Ajjai Alva, Leonard J. Appleman, Winston Tan, Ulka Vaishampayan, Raphaelle Porcu, Darren Tayama, Edward E. Kadel III, Kobe C. Yuen, Asim Datye, Andrew J. Armstrong, and Daniel P. Petrylak

4757 A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1

Sarah A. Weiss, Dijana Djureinovic, Shlomit Jessel, Irina Krykbaeva, Lin Zhang, Lucia Jilaveanu, Amanda Ralabate, Barbara Johnson, Neta Shanwetter Levit, Gail Anderson, Daniel Zelterman, Wei Wei, Amit Mahajan, Ovid Trifan, Marcus Bosenberg, Susan M. Kaech, Curtis J. Perry, William Damsky, Scott Gettinger, Mario Sznol, Michael Hurwitz, and Harriet M. Kluger

PRECISION MEDICINE AND IMAGING

4768 Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer

Laetitia Marisa, Yuna Blum, Julien Taieb, Mira Ayadi, Camilla Pilati, Karine Le Malicot, Côme Lepage, Ramon Salazar, Daniela Aust, Alex Duval, Héléne Blons, Valérie Taly, David Gentien, Audrey Rapinat, Janick Selves, Sophie Mouillet-Richard, Valérie Boige, Jean-François Emile, Aurélien de Reyniès, and Pierre Laurent-Puig

4781 Rapid Serial Immunoprofiling of the Tumor Immune Microenvironment by Fine Needle Sampling

Juhyun Oh, Jonathan C.T. Carlson, Christian Landeros, Hakho Lee, Scott Ferguson, William C. Faquin, John R. Clark, Mikael J. Pittet, Sara I. Pai, and Ralph Weissleder

4794 Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform

Durga Udayakumar, Ze Zhang, Yin Xi, Durgesh K. Dwivedi, Michael Fulkerson, Sydney Haldeman, Tiffani McKenzie, Quratulain Yousuf, Allison Joyce, Asghar Hajibeigi, Hollis Notgrass, Alberto Diaz de Leon, Qing Yuan, Matthew A. Lewis, Ananth J. Madhuranthakam, Robert C. Sibley, Roy Elias, Junyu Guo, Alana Christie, Renée M. McKay, Jeffrey A. Cadeddu, Aditya Bagrodia, Vitaly Margulis, James Brugarolas, Tao Wang, Payal Kapur, and Ivan Pedrosa

4807 Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma

Zeynep B. Zengin, Caroline Weipert, Nicholas J. Salgia, Nazli Dizman, Joann Hsu, Luis Meza, Alexander Chehrizi-Raffle, Ramya Muddasani, Sabrina Salgia, Jasnoor Malhotra, Neal Chawla, Errol J. Philip, Lesli Kiedrowski, Benjamin L. Maughan, Nityam Rathi, Divyam Goel, Toni K. Choueiri, Neeraj Agarwal, and Sumanta K. Pal

4814 The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

Max J. Gordon, Andy Kaempf, Andrea Sitlinger, Geoffrey Shouse, Matthew Mei, Danielle M. Brander, Tareq Salous, Brian T. Hill, Hamood Alqahtani, Michael Choi, Michael C. Churnetski, Jonathon B. Cohen, Deborah M. Stephens, Tanya Siddiqi, Xavier Rivera, Daniel Persky, Paul Wisniewski, Krish Patel, Mazyar Shadman, Byung Park, and Alexey V. Danilov

TABLE OF CONTENTS

- 4825 Differential Effect of Graft-versus-Host Disease on Survival in Acute Leukemia according to Donor Type**
Takaaki Konuma, Junya Kanda, Yachiyo Kuwatsuka, Masamitsu Yanada, Tadakazu Kondo, Shigeki Hirabayashi, Shinichi Kako, Yu Akahoshi, Naoyuki Uchida, Noriko Doki, Yukiyasu Ozawa, Masatsugu Tanaka, Tetsuya Eto, Masashi Sawa, Satoshi Yoshioka, Takafumi Kimura, Yoshinobu Kanda, Takahiro Fukuda, Yoshiko Atsuta, and Fumihiko Kimura
- 4883 RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer**
Siang-Boon Koh, Kenneth Ross, Steven J. Isakoff, Nsan Melkonjan, Lei He, Karina J. Matissek, Andrew Schultz, Erica L. Mayer, Tiffany A. Traina, Lisa A. Carey, Hope S. Rugo, Minetta C. Liu, Vered Stearns, Adam Langenbucher, Srinivas Vinod Saladi, Sridhar Ramaswamy, Michael S. Lawrence, and Leif W. Ellisen
- 4898 ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate Cancer**
Zhe Tang, Patrick G. Pilié, Chuandong Geng, Ganiraju C. Manyam, Guang Yang, Sanghee Park, Daoqi Wang, Shan Peng, Cheng Wu, Guang Peng, Timothy A. Yap, Paul G. Corn, Bradley M. Broom, and Timothy C. Thompson
- 4910 Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a TP53- and BAX-Dependent Manner**
Tingting Liu, Vi Lam, Elana Thieme, Duanchen Sun, Xiaoguang Wang, Fei Xu, Lili Wang, Olga V. Danilova, Zheng Xia, Jeffrey W. Tyner, Stephen E. Kurtz, and Alexey V. Danilov
- 4923 BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program**
Dae-Hwan Kim, Duanchen Sun, William K. Storck, Katherine Welker Leng, Chelsea Jenkins, Daniel J. Coleman, David Sampson, Xiangnan Guan, Anbarasu Kumaraswamy, Eva S. Rodansky, Joshua A. Urrutia, Jacob A. Schwartzman, Chao Zhang, Himisha Beltran, Mark P. Labrecque, Colm Morrissey, Jared M. Lucas, Ilsa M. Coleman, Peter S. Nelson, Eva Corey, Samuel K. Handelman, Jonathan Z. Sexton, Rahul Aggarwal, Wassim Abida, Felix Y. Feng, Eric J. Small, Daniel E. Spratt, Armand Bankhead III, Arvind Rao, Emily M. Gesner, Sarah Attwell, Sanjay Lakhota, Eric Campeau, Joel A. Yates, Zheng Xia, and Joshi J. Alumkal
- TRANSLATIONAL CANCER MECHANISMS AND THERAPY**
- 4836 A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes**
Carla Calagua, Miriam Ficial, Caroline S. Jansen, Taghreed Hirz, Luke del Balzo, Scott Wilkinson, Ross Lake, Anson T. Ku, Olga Voznesensky, David B. Sykes, Philip J. Saylor, Huihui Ye, Sabina Signoretti, Haydn Kissick, Adam G. Sowalsky, Steven P. Balk, and David J. Einstein
- 4848 Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study**
Richard S. Finn, Masatoshi Kudo, Ann-Lii Cheng, Lucjan Wyrwicz, Roger K.C. Ngan, Jean-Frederic Blanc, Ari D. Baron, Arndt Vogel, Masafumi Ikeda, Fabio Piscaglia, Kwang-Hyub Han, Shukui Qin, Yukinori Minoshima, Michio Kanekiyo, Min Ren, Ryo Dairiki, Toshiyuki Tamai, Corina E. Dutcus, Hiroki Ikezawa, Yasuhiro Funahashi, and Thomas R. Jeffrey Evans
- 4859 Memory-like Differentiation Enhances NK Cell Responses to Melanoma**
Nancy D. Marin, Bradley A. Krasnick, Michelle Becker-Hapak, Leah Conant, Simon P. Goedegebuure, Melissa M. Berrien-Elliott, Keenan J. Robbins, Jennifer A. Foltz, Mark Foster, Pamela Wong, Celia C. Cubitt, Jennifer Tran, Christopher B. Wetzel, Miriam Jacobs, Alice Y. Zhou, David Russler-Germain, Lynne Marsala, Timothy Schappe, Ryan C. Fields, and Todd A. Fehniger
- 4870 Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer**
Carmine De Angelis, Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraghavan, Sarmistha Nanda, Lanfang Qin, Vidyalakshmi Sethunath, Tao Wang, Susan G. Hilsenbeck, Matteo Benelli, Ilenia Migliaccio, Cristina Guarducci, Luca Malorni, Lacey M. Litchfield, Jiangang Liu, Joshua Donaldson, Pier Selenica, David N. Brown, Britta Weigelt, Jorge S. Reis-Filho, Ben H. Park, Sara A. Hurvitz, Dennis J. Slamon, Mothaffar F. Rimawi, Valerie M. Jansen, Rinath Jeselsohn, C. Kent Osborne, and Rachel Schiff
- LETTER TO THE EDITOR**
- 4937 NIR Fluorescence Imaging of Colon Cancer with cRGD-ZW800-1—Letter**
Susanne Kossatz and Johannes Notni
- 4938 NIR Fluorescence Imaging of Colon Cancer With cRGD-ZW800-1—Response**
Cornelis F.M. Sier and Alexander L. Vahrmeijer

TABLE OF CONTENTS

CORRECTIONS

4939 Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

Carmine De Angelis, Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraraghavan, Sarmistha Nanda, Lanfang Qin, Vidyalakshmi Sethunath, Tao Wang, Susan G. Hilsenbeck, Matteo Benelli, Ilenia Migliaccio, Cristina Guarducci, Luca Malorni, Lacey M. Litchfield, Jiangang Liu, Joshua Donaldson, Pier Selenica, David N. Brown, Britta Weigelt, Jorge S. Reis-Filho, Ben H. Park, Sara A. Hurvitz, Dennis J. Slamon, Mothaffar F. Rimawi, Valerie M. Jansen, Rinath Jeselsohn, C. Kent Osborne, and Rachel Schiff

4940 Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

Arta M. Monjazeb, Anita Giobbie-Hurder, Ana Lako, Emily M. Thrash, Ryan C. Brennick, Katrina Z. Kao, Claire Manuszak, Ryan D. Gentzler, Anteneh Tesfaye, Salma K. Jabbour, Olatunji B. Alese, Osama E. Rahma, James M. Cleary, Elad Sharon, Harvey J. Mamon, May Cho, Howard Streicher, Helen X. Chen, Mansoor M. Ahmed, Adrian Mariño-Enriquez, Seunghee Kim-Schulze, Sacha Gnjatich, Emanuel Maverakis, Alina I. Marusina, Alexander A. Merleev, Mariano Severgnini, Kathleen L. Pfaff, James Lindsay, Jason L. Weirather, Srinika Ranasinghe, Alexander Spektor, Scott J. Rodig, F. Stephen Hodi, and Jonathan D. Schoenfeld

4941 Correction: Effects of Tobacco Smoking On the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma

Janis V. de la Iglesia, Robbert J.C. Slebos, Laura Martin-Gomez, Xuefeng Wang, Jamie K. Teer, Aik Choon Tan, Travis A. Gerke, Garrick Aden-Buie, Tessa van Veen, Jude Masannat, Ritu Chaudhary, Feifei Song, Michelle Fournier, Erin M. Siegel, Matthew B. Schabath, J. Trad Wadsworth, Jimmy Caudell, Louis Harrison, Bruce M. Wenig, Jose Conejo-Garcia, Juan C. Hernandez-Prera, and Christine H. Chung

4942 Correction: Downregulation of MicroRNA-644a Promotes Esophageal Squamous Cell Carcinoma Aggressiveness and Stem Cell-like Phenotype via Dysregulation of PITX2

Jia-Xing Zhang, Zhen-Hua Chen, Yi Xu, Jie-Wei Chen, Hui-Wen Weng, Miao Yun, Zou-San Zheng, Cui Chen, Bing-Li Wu, En-Min Li, Jian-Hua Fu, Sheng Ye, and Dan Xie

EDITOR'S NOTE

4943 Editor's Note: Dual Targeting of Wild-Type and Mutant p53 by Small-molecule RITA Results in the Inhibition of N-Myc and Key Survival Oncogenes and Kills Neuroblastoma Cells *In Vivo* and *In Vitro*


Mikhail Burmakin, Yao Shi, Elisabeth Hedström, Per Kogner, and Galina Selivanova

AC AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

Antigen-presenting cells expressing MHC II (green) form niches together with exhausted progenitor T cells expressing CD8 (red, membranous) and TCF1 (light blue, nuclear). Although prostate cancer is classically nonimmunogenic, these tumor-infiltrating immune populations are seen in a uniquely immunogenic subset of localized prostate cancer and are consistent with an antitumor immune response, which may be further expanded by immune checkpoint blockade. For details, see the article by Calagua and colleagues on page 4836 of this issue. (Image created by C.S. Jansen, co-author.)



doi: 10.1158/1078-0432.CCR-27-17-CVR

Clinical Cancer Research

27 (17)

Clin Cancer Res 2021;27:4665-4943.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/27/17>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/27/17>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.